This retrospective multicenter study included metastatic renal cell carcinoma (mRCC).
mRCC was treated with antiangiogenics and glandular metastasis (GM) was recorded.
Metastases to the pancreas, adrenal gland, breast, thyroid, or parotid defined GM.
Patients with GM as first metastatic presentation had longer overall survival.
The GM localization was an independent prognostic factor for survival.